CMO Patheon is investing in a U.K. site to increase capacity and add capabilities, including automated capsule filling. The expansion comes as Patheon prepares to merge with DSM's pharma business under the ownership of JLL Partners.
International Chemical Investors Group (ICIG) has nabbed another operation to fold into its contract manufacturing arm Corden Pharma group: Peptisyntha, a Brussels, Belgium-based custom manufacturer of peptides for pharmaceuticals. It will become its third site offering this service.
Irish drugmaker Amarin continues to stack up manufacturing partners for the API for its fish oil drug Vascepa. While its decision to launch the drug without a partner has meant slow going in getting it to market, Amarin has pushed ahead with deals with contract manufacturers, hoping to get FDA approval for a fourth API maker.
The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.
In recent years, it has become dramatically easier and quicker to create a virtual drug-development company. Today it is even possible to take virtual to its logical extreme: a zero-person biotech company.
Besides making drugs for other companies and selling over-the-counter products in India, contract manufacturer Piramal Enterprises does its own drug development and owns a big stake in India's cellphone market as well as a piece of a transport lender.
At a time when the FDA is urging drugmakers to work more closely with contractors on quality, Roche says it is already doing it.
Contract manufacturing has become a hot investment, and Novartis thinks it may be time to cash in. The Swiss drugmaker and its partners are looking at selling their joint venture, LTS Lohmann.
Another of India's large generic drugmakers has found itself in serious problems with the FDA. Just a week after Ranbaxy Laboratories' $500 million settlement, Wockhardt says the FDA has issued an import alert that could cost it $100 million in lost sales.
Pfizer's "external partner management" process is not exactly "American Idol" and Pfizer's John F. Kelly is not exactly Simon Cowell, but this year the Pfizer Global Supply (PGS) unit will go through the exercise of turning a handful or two of its more than 200 contractors into stars.